Therapeutics: Glycogen synthase kinase 3 β (GSK3B); microtubule-associated protein τ (tau; MAPT; FTDP-17)


INDICATION: Alzheimer's disease (AD)

In vitro and rodent studies identified an isonicotinamide-based GSK3β inhibitor that could help treat AD or other tauopathies.

Read the full 210 word article

How to gain access

Continue reading with a
two-week free trial.